Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
763 studies found for:    Erbitux
Show Display Options
Rank Status Study
1 Terminated An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Condition: Colorectal Neoplasm
Intervention: Drug: Cetuximab
2 Unknown  Reirradiation and Erbitux in the HNSCC
Condition: Head Neck Cancer Squamous Cell.
Intervention: Drug: Erbitux
3 Completed A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
Condition: Mucinous Gastrointestinal Adenocarcinoma
Intervention: Drug: cetuximab
4 Completed
Has Results
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma
Interventions: Drug: Cetuximab;   Drug: Bevacizumab
5 Terminated EMMA-1 (Erbitux for Multiple Myeloma)
Condition: Multiple Myeloma
Intervention: Drug: Cetuximab +/- Dexamethasone
6 Terminated An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Condition: Carcinoma, Squamous Cell
Intervention: Drug: Cetuximab
7 Active, not recruiting Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Conditions: Glioblastoma Multiforme (GBM);   ANAPLASTIC ASTROCYTOMA (AOA)
Intervention: Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab
8 Recruiting Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Cetuximab
9 Completed Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
Condition: Recurrent Head and Neck Cancer
Intervention: Drug: IPI-926 and Cetuximab
10 Completed Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Cetuximab
11 Completed A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Condition: Colorectal Neoplasms
Intervention: Drug: Erbitux (Cetuximab)
12 Active, not recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
13 Recruiting Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Conditions: Glioblastoma Multiforme;   Fibrillary Astrocytoma of Brain;   Glioma of Brainstem;   Anaplastic Astrocytoma;   Pilomyxoid Astrocytoma;   Mixed Oligodendroglioma-Astrocytoma;   Brain Stem Glioma;   Diffuse Intrinsic Pontine Glioma
Intervention: Drug: SIACI of Erbitux and Bevacizumab
14 Completed
Has Results
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
Condition: Cancer of Head and Neck
Interventions: Drug: Erbitux, Paclitaxel & Carboplatin;   Radiation: Radiation
15 Completed Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®
Condition: Head and Neck Carcinoma
Interventions: Other: Radiotherapy + Erbitux® + placebo;   Other: Radiotherapy+Erbitux+OTD70DERM
16 Completed An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Cetuximab
17 Completed An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Conditions: Carcinoma, Non-Small-Cell Lung;   Neoplasm Metastasis
Intervention: Drug: Cetuximab
18 Active, not recruiting Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Oral Cancer;   Oropharyngeal Carcinoma
Intervention: Drug: Neo-adjuvant Erbitux-based chemotherapy
19 Recruiting Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Conditions: Carcinoma, Squamous Cell;   Carcinoma, Squamous Cell of Head and Neck
Intervention: Drug: Intraarterial Cetxuimab (Erbitux)
20 Withdrawn A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Condition: Neoplasms, Squamous Cell
Intervention: Drug: Cetuximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.